Texas Hormone Therapy Compliance for Med Spas 2026: TRT, HRT, DEA & DSHS Requirements

Why Hormone Therapy Compliance Is More Complex Than Other Med Spa Services

Most med spa compliance issues involve the Texas Medical Board and physician delegation. Hormone therapy adds a second federal layer: the Drug Enforcement Administration. Testosterone cypionate, testosterone enanthate, testosterone pellets, and certain other hormone preparations are Schedule III controlled substances under the Controlled Substances Act. That means every element of the DEA's controlled substance handling framework applies to your hormone therapy program — registration, storage, record-keeping, and disposal.

This is not a technicality that enforcement agencies overlook. DEA inspections of med spas offering testosterone programs have increased nationally, and Texas — as one of the largest TRT markets in the country — has seen significant enforcement activity. Practices operating without proper DEA registration are not just at risk of fines; they face potential federal criminal exposure.

Layered on top of DEA requirements are Texas Medical Board prescribing standards, Texas State Board of Pharmacy oversight of compounded hormones, and DSHS facility requirements. Getting all three right simultaneously is what a compliant Texas hormone therapy program looks like.

DEA Registration: The Non-Negotiable First Step

Before your Texas med spa can store, prescribe, dispense, or administer testosterone or other Schedule III hormone preparations, the practice location must hold a valid DEA registration. This is separate from the prescribing physician's individual DEA number — though the physician must also hold their own DEA registration.

Practice Location Registration

DEA registrations are tied to specific physical locations. If your practice has two locations and both offer TRT, each needs its own DEA registration. A physician's personal DEA number does not authorize controlled substance handling at a practice location — the practice itself must be registered.

To register: apply through the DEA Diversion Control Division. For a medical practice dispensing or administering Schedule III substances, you will register as a practitioner. The registration must be renewed annually and posted at the registered location.

Storage Requirements

Schedule III controlled substances must be stored in a securely locked, substantially constructed cabinet or safe. "Locked drawer in the treatment room" does not meet this standard. The storage must be separate from general medical supplies and accessible only to authorized personnel. A log of controlled substance inventory, receipt, and administration must be maintained and available for DEA inspection at any time.

Record-Keeping

Federal law requires a complete record of every controlled substance received, dispensed, and administered. For a TRT program, this means documenting every testosterone dose administered, including the patient name, date, drug name, strength, quantity, and administering provider. These records must be maintained for a minimum of two years and made available to DEA inspectors on request.

TMB Prescribing Requirements for Hormone Therapy

Separate from DEA requirements, the Texas Medical Board governs how hormone therapy is prescribed. The standard is a legitimate patient-prescriber relationship, a clinically appropriate evaluation, and documented medical necessity. This is the same standard that applies to all TMB-regulated prescribing, but hormone therapy has some specific considerations.

Patient Evaluation Before Prescribing

Prescribing testosterone based solely on a symptom questionnaire — without laboratory confirmation of low testosterone and a clinical evaluation — is a TMB prescribing violation. The evaluation must include:

• Complete medical and medication history
• Review of symptoms consistent with hypogonadism or hormonal deficiency
• Laboratory confirmation (see lab requirements below)
• Assessment of contraindications — prostate cancer history, polycythemia, severe sleep apnea
• Discussion of risks, benefits, and alternatives documented in the chart

Lab Requirements — Standard of Care

Texas does not mandate a specific lab panel by statute, but the standard of care for hormone therapy initiation — and the baseline TMB inspectors expect to see — includes:

• For TRT (male patients): Total testosterone (morning draw), free testosterone, CBC with hematocrit, PSA (patients over 40), lipid panel, LH and FSH, comprehensive metabolic panel
• For female hormone therapy (HRT): Estradiol, FSH, total and free testosterone, SHBG, CBC, comprehensive metabolic panel, and thyroid panel where indicated
• Monitoring labs: Hematocrit at 3 months (critical for TRT — testosterone raises red blood cell production, and elevated hematocrit is a serious cardiovascular risk); repeat testosterone levels at 6–8 weeks after initiation to assess response and guide dose adjustment

Every lab result must be in the patient's chart. Prescribing without labs or with labs that are months old at the time of initiation will not survive a TMB chart review.

Compounded Hormone Therapy: What TSBP Requires

Unlike compounded GLP-1 medications — which faced specific FDA shortage-related enforcement — compounded testosterone and bio-identical hormones have a longer history under traditional pharmacy compounding frameworks. Compounded testosterone from a Texas State Board of Pharmacy (TSBP)-licensed 503A pharmacy remains permissible when:

• Prescribed for a specific patient with a valid prescription from a licensed Texas prescriber
• There is a documented clinical basis for the compounded formulation (e.g., need for a specific concentration, route of administration, or absence of commercial equivalent)
• The compounding pharmacy holds a valid TSBP license and complies with USP Chapter 795 (non-sterile compounding) or USP Chapter 797 (sterile compounding, for injectable formulations)
• Proper labeling requirements are met, including beyond-use dates and patient-specific labeling

Pellet Therapy Specifically

Testosterone pellet implantation is a popular TRT delivery method in Texas med spas. Pellets are a compounded product — there is no FDA-approved testosterone pellet. The pellet itself comes from a compounding pharmacy under the framework above. The implantation procedure is a minor surgical procedure requiring the physician or appropriately delegated provider to be trained in the technique, maintain a sterile field, and follow written protocols covering the procedure, potential complications (extrusion, infection), and follow-up care. See our post on Texas med spa medical director requirements for how delegation of minor procedures like pellet insertion works under TMB rules.

Who Can Administer Hormone Therapy at a Texas Med Spa

Hormone therapy administration follows the same delegation framework as other medical procedures. An RN can administer testosterone injections under a physician's written protocol. A trained RN or APRN can perform testosterone pellet insertions if specifically delegated and trained. PAs can administer under their supervising physician's protocol.

The prescription must come from a licensed Texas prescriber with DEA registration. The administering provider follows a written protocol. The physician remains immediately available. This is the same framework covered in our post on who can perform delegated acts in Texas med spas.

Texas Health & Safety Code: Dangerous Drug and Controlled Substance Rules

Beyond DEA requirements, Texas has its own controlled substance and dangerous drug framework under Texas Health & Safety Code Chapter 483. For med spas, the relevant points include:

• Dangerous drugs (including non-controlled hormones like estradiol and progesterone) can only be dispensed on the prescription of a licensed practitioner
• A practitioner may dispense drugs in the usual course of professional practice — meaning your physician can dispense hormone preparations directly to patients, but only within proper prescribing and record-keeping frameworks
• Violations of Chapter 483 can result in state criminal charges separate from any DEA or TMB action

Monitoring and Follow-Up Documentation

A hormone therapy program that has strong intake documentation but no ongoing monitoring documentation will fail a TMB review. Every active patient should have:

• Follow-up lab results at the intervals established in the prescribing protocol (typically 6–8 weeks post-initiation, then every 3–6 months)
• Documented clinical assessment at each follow-up — symptom response, side effects, dose adjustments and the clinical basis for any changes
• Hematocrit monitoring for TRT patients — this is non-negotiable given the cardiovascular risk of untreated polycythemia
• PSA monitoring for male patients over 40 at appropriate intervals
• Documented patient education about hormone therapy risks, including the patient's signature acknowledging they have received and understood the information

Common Compliance Failures in Texas Hormone Therapy Programs

Based on regulatory review patterns, the most frequent gaps in Texas med spa hormone therapy programs include:

• No DEA registration at the practice location — the single most serious and common violation
• DEA registration at one location not covering additional locations for multi-site practices
• Inadequate controlled substance storage — unlocked cabinets or storage that does not meet DEA substantially-constructed requirements
• Missing or incomplete controlled substance logs — no record of every testosterone dose administered
• Prescribing without labs — initiating TRT based on symptoms alone
• No hematocrit monitoring for TRT patients
• Compounded hormone documentation gaps — no documented clinical basis for choosing compounded over FDA-approved preparations
• Pellet insertion without proper sterile technique or training documentation

See our guide to common med spa compliance violations for the full picture of what TMB and federal inspectors flag. For how to structure the SOPs that govern these programs, see our med spa SOP guide.

Medical Director Liability for Hormone Therapy Programs

Hormone therapy programs carry significant medical director liability because of the controlled substance component and the ongoing monitoring requirements. A physician who signs protocols for a TRT program and then has no real involvement in patient oversight — no chart reviews, no lab result follow-ups, no response to concerning hematocrit values — is exposed to both TMB disciplinary action and potential DEA scrutiny around prescribing patterns.

The medical director's involvement in a hormone therapy program should be documented and active: regular chart reviews, participation in protocol updates when monitoring reveals patterns, and clear escalation procedures for concerning lab values. For more on how to structure this relationship, see our guide on med spa medical director liability.